Biotechnology Venture Capital Best Practices is an authoritative, insider s perspective on the ins and outs of the biotech industry for VCs, entrepreneurs, and industry executives. Featuring managing partners at top VC firms and CEOs of funded biotechnology companies, these experts provide best practices for venture capitalists and entrepreneurs at all stages of an investment with a focus on raising capital, establishing valuations, determining exit strategies, and structuring deals. From spotting opportunities in the industry to developing a solid leadership plan, these industry leaders discuss characteristics that make a good partner, key tools and methods for determining valuations, strategies for conducting due diligence, and negotiation techniques for producing a successful deal. These seasoned experts reveal their advice for increasing fund-raising, assessing potential ROI, evaluating the timeline of a deal, and understanding management team criteria, as well as provide insights for hedging risks and avoiding common mistakes. The different niches presented and the breadth of perspectives represented enable readers to get inside some of leading minds of today, as these insiders offer up their thoughts around the keys to successful deal-making in this rapidly evolving industry. Inside the Minds provides readers with proven business intelligence from C-Level executives (Chairman, CEO, CFO, CMO, Partner) from the world s most respected companies nationwide, rather than third-party accounts from unknown authors and analysts. Each chapter is comparable to an essay/thought leadership piece and is a future-oriented look at where an industry, profession, or topic is headed and the most important issues for the future. Through an exhaustive selection process, each author was hand-picked by the Inside the Minds editorial board to author a chapter for this book.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
1. Peter G. Ulrich, Co-Founder, President and Chief Executive Officer, TargeGen Inc. Finding and Meeting Needs in Vascular Biology 2. Francois Ferre, Ph.D., Founder, Co-President and Co-Chief Executive Officer, and Magda Marquet, Ph.D, . Founder, Co-President and Co-Chief Executive Officer, Althea Technologies Inc. Harnessing the Power of Venture Capital for Growth in the Biotech Field 3. Laura K. Shawver, Ph.D., President and CEO. Phenomix Corporation Meeting the Challenge of Change in the World of Biotechnology Venture Capital Funding 4. Scott Salka, Chief Executive Officer, Ambit Biosciences Moving in New Directions: Evolution and Funding Strategies in the Biotech Realm 5. Seth A. Rudnick, M.D., General Partner, and John Pacifico, Analyst, Canaan Partners Driving Successful Venture Capital Investments 6. Michael Raab, Partner, New Enterprise Associates The Process of Obtaining Venture Capital Financing in Biotech 7. Amir Nashat, Ph.D. , General Partner, Polaris Venture Partners Funding Innovation in the Biotech Industry 8. Gary J. Kurtzman, M.D., Vice President, Life Sciences, Safeguard Scientifics Investing in Solutions in the Biotech Industry 9. Daniel K. Turner III, Managing Director, Montreux Equity Partners Therapeutic Product Investments in Biotech: Helping Start-ups Succeed 10. Stephen Knight, M.D., Managing Partner, Fidelity Biosciences The Varied Roles of VC Firms in the Biotech Industry 11. Fred Craves, Ph.D., Investment Partner, Managing Director and Founder, and William Gerber, M.D., Investment Partner, Bay City Capital Funding and Exiting a Biotech Firm: Helpful Hints and Traps to Avoid
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.